Explore today’s hemophilia treatment landscape. Learn about factor replacement, non-factor therapies, and gene therapy advances discussed at the Bleeding Disorders Conference.

Women and girls with bleeding disorders face delays in diagnosis and care. Learn how research and community voices are changing the future of treatment.

From quality of life to new therapies, families and researchers came together to share insights and inspire one another.

The National Bleeding Disorders Foundation’s (NBDF) 77th Annual Bleeding Disorders Conference (BDC) is here! Learn, connect, and explore the latest in care, research, and community support.

Learning about von Willebrand disease at NBDF’s VWD Masterclass: diagnosis, treatment history, therapies, and community perspectives.

Discover how patient registries like ATHN, Community Counts, and NBDF’s Community Voices in Research (CVR) turn lived experiences into data that improves care, drives therapies, and advances research.

Discover the winners of NBDF’s 2025 Awards of Excellence, honoring volunteers, providers, researchers, advocates, and leaders driving progress in the bleeding disorders community.

Spark Biomedical is developing innovative solutions to shorten the time it takes women with heavy menstrual bleeding to get effective treatment and care.

Concizumab-mtci is a subcutaneous therapy, which is developed using a synthetically produced (recombinant) antibody derived from a single cell clone, designed to be equally effective in individuals with hemophilia A and B, irrespective of inhibitor status.

Explore the latest updates on federal budget reconciliation, healthcare lawsuits, and state-level policy changes impacting bleeding disorders. Learn how NBDF is advocating for access, funding, and patient protections.